Clinical isolates of Staphylococcus and Arthrobacter spp. were screened for lincosamide resistance. Six different patterns of resistance were found. Strains designated SF27 and SF28 showed low-level resistance to lincosamides: one was susceptible to erythromycin (SF27) and the other was resistant (SF28). Analysis of ribosomes from the resistant strains in an in vitro poly(U)-dependent protein-synthesizing system showed that ribosomes of both strains were sensitive to lincomycin and clindamycin. Four patterns of high-level resistance to lincosamides were observed (strains SF4, SF19, SF30, and SF31). All of these except SF30 had ribosomes which were highly resistant in vitro to the antibiotics and showed a close correlation with results of the in vivo experiments. In vivo protein synthesis by strain SF30 was resistant to lincomycin and sensitive to clindamycin, whereas the ribosomes were sensitive when assayed in vitro. Lincosamide-inactivating enzymes were not detected in cell extracts of the six resistant strains. Strains SF19 and SF31 demonstrated two ribosomemediated lincosamides resistance mechanisms that were not previously reported. Both strains were highly resistant to lincosamides and susceptible to erythromycin, but SF19 was also highly resistant to oleandomycin and partially resistant to various macrolides.
Lincosamide antibiotics efficiently inhibit protein synthesis in gram-positive bacteria but have low activity against many gram-negative bacteria. Lincomycin is among the best known representatives of the group, together with its derivatives clindamycin (7-chloro-7-deoxylincomycin) and celesticetin. Lincomycin has been shown to bind to the 50S ribosomal subunits (5) and to act on aminoacyl-tRNA binding and the peptidyl transferase reaction (3, 20, 26) . The structure of lincosamides is chemically distinct from that of macrolide and streptogramin B-type antibiotics. Resistance to lincosamide antibiotics is nearly always associated with coresistance to macrolides and streptogramin B-type antibiotics in the so-called MLS phenotype. The MLS antibiotics are closely related in their modes of action, and they appear to share a common or overlapping binding site in the ribosome. The MLS resistance phenotype is found widely among Staphylococcus (4, 27, 28) , Streptococcus (7, 10) , Corynebacterium (12) , Bacteroides (29, 36) , Clostridium (17) , and Bacillus (15) clinical isolates, as well as among the erythromycin producers (18, 30) . The molecular basis for resistance in clinical isolates has been attributed to N6-dimethylation of adenine in 23S rRNA (22, 23) , which renders the ribosomes insensitive to these antibiotics. A similar situation was found in the erythromycin producer Streptomyces eythraeus (32, 33) .
Few reports exist in the literature about resistance to lincosamides in organisms that are simultaneously susceptible to erythromycin and other macrolides. However, two such resistance phenotypes have been described in Staphylococcus species: one is associated with antibiotic degradation and the other is unassociated with any apparent drug inactivation (14) . In addition, a clinical isolate of Staphylococcus haemolyticus has been reported to inactivate lincomycin and clindamycin while being susceptible to macrolides and streptogramin B-type antibiotics (24) .
In this communication, we discuss several Staphylococ-* Corresponding author.
cus and nonpathogenic Arthrobacter clinical isolates which present novel phenotypes of resistance to lincosamides.
MATERIALS AND METHODS Bacterial strains, culture conditions, and determination of MICs. Clinical isolates were obtained from Hospital Nuestra Seniora de Covadonga (Oviedo) and selected for resistance to lincomycin and/or clindamycin in agar-disk diffusion tests (5 ,ug per disk) with Mueller-Hinton agar plates. On the basis of morphological, physiological, and biochemical tests, the isolates were identified as staphylococci and coryneform bacteria. Strain designations for these isolates and for antibiotic-susceptible standard strains are shown in Table 1 .
The organisms screened by disk diffusion assays were grown overnight at 37°C in 2 ml of Luria broth, transferred onto Mueller-Hinton agar plates containing different antibiotic concentrations by using a Steers replicator (34) , and incubated for 16 h at 37°C.
All the cultures were grown aerobically in Luria broth at 37°C and shaken at 250 rpm in a Gallenkamp orbital incubator. For small cultures (10 to 25 ml), cells were grown in 100-or 250-ml Erlenmeyer flasks. For batch cultures (300 to 500 ml), cells were grown in 1-liter Erlenmeyer flasks. Growth was monitored by observing the A6. in a Unicam SP 1700 spectrophotometer.
In vivo protein synthesis. Cultures were grown overnight at 37°C in M9 medium (25) supplemented with 0.1% (wt/vol) yeast extract and 0.025% (wt/vol) casein hydrolysate. A 10-ml sample of fresh medium was inoculated with 0.5 ml of the overnight culture and incubated until the A6. was between 0.4 and 0.6. Samples (0.5 ml) were incubated for 5 min at 37°C with different concentrations of the antibiotics and labeled for 15 min after the addition of 1 , uCi of [3H]leucine per ml. The labeling was stopped by the addition of 1 ml of 15% (wt/vol) ice-cold trichloroacetic acid (TCA). After standing at 4°C for at least 30 min, the samples were heated at 90°C for 15 min, filtered through Whatman GF/C filters, and dried, and the radioactivity in the filters was counted. Isolation of ribosomes. Ribosomes were isolated by a previously described procedure (31) with some modifications. Thus, cells were broken by disintegration with glass beads (diameter, 0.10 to 0.11 mm) in a Braun model MSK mechanical homogenizer (Braun, Melsungen, Federal Republic of Germany) for two periods of 2 min with intermittent cooling in solid CO2. The concentration of ribosomes in clean preparations (A26/A280, .1.8) was calculated assuming that 1 A260 contains 29.4 pmol of ribosomes. These were divided into 100-,ul aliquots and kept frozen at -70°C until used.
Poly(U)-dependent protein synthesis. To test the sensitivity of ribosomes to the set of test antibiotics, an in vitro translation system dependent on the presence of a synthetic messenger was used. As a source of soluble factors, S-100 from a lincosamide-susceptible strain, Streptomyces antibioticus ATCC 11891, was used. The S-100 represents the supernatant obtained by layering a cell extract over 2 volumes of high-salt buffer (1 M NH4Cl) followed by centrifugation at 100,000 x g and further dialysis against low-salt buffer. Ribosomes (20 to 50 pmol) were incubated with different concentrations of the antibiotics at room temperature for 5 min. The reaction was initiated by adding (in a 60-,u final volume) 12 ,u1 of the S-100 and 30 ,u1 of assay mixture. The assay mixture contained 40 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)-KOH (pH 7.6) at 20°C, 100 mM KCl, 17 mM MgCl2, 5 mM ATP, 0.7 mM GTP, 15 mM phosphoenolpyruvate, 4.8 ,ug of pyruvate kinase, 30 ,ug of poly(U), 5 ,ug of tRNAPh,, and 1.6 ,uCi of [3H]phenylalanine. The mixture was incubated at 37°C, and samples (10 p.1) were removed at intervals and added to 1 ml of 10% (wt/vol) TCA. After being heated at 90°C for 15 min, the samples were filtered through fiber glass disks (Whatman GF/C), washed with 5 volumes of 5% (wt/vol) TCA, and dried, and the radioactivity was counted.
Antibiotic-inactivation assays. The presence of lincosamide-inactivating enzymes in the lincosamide-resistant strains was tested with both intact cells and cell extracts. (i) Intact cells. Cells from 150 ml of an overnight culture in L broth were collected by centrifugation, washed once in 0.01 M sodium phosphate buffer (pH 7.0), and suspended in 3 ml of the same buffer. Lincomycin or clindamycin (40 ,ug/ml) was added, and the cells were incubated at 37°C. At zero time and after 8 h of incubation, the samples were centrifuged in an Eppendorf minifuge and 10 p. together with 1 mM ATP or acetyl coenzyme A as the potential cofactor for drug inactivation. A 10-,ul sample of the assay mixture was spotted onto a paper disk, and the antibiotic activity was measured by the microbiological assay described in i. 
RESULTS
Isolation of lincosamide-resistant strains. A total of 1,213 clinical isolates, mainly staphylococci and coryneform bacteria, were screened by antibiotic disk tests for resistance to lincomycin and/or clindamycin. Of these, 289 isolates (23.8%) were found to be resistant to one or both antibiotics (each disk contained 5 p.g of antibiotic), and several isolates, each corresponding to one of six patterns of resistance to lincosamides and macrolides, were selected. Representatives of these groups, strains designated SF4, -19, -27, -28, -30, and -31, are shown in Table 1 . We did not find any relationship between species or pathogenicity of bacteria and resistance pattern. Two types of low-level resistance to lincomycin were found: one of susceptibility to erythromycin (strain SF27) and the other of resistance to low levels (MIC, 25 ,ug/ml) of erythromycin (strain SF28). Both strains were also partially resistant to clindamycin and celesticetin and very susceptible to the other macrolides. Four types of high-level resistance to lincomycin were detected: (i) highlevel resistance to all the MLS antibiotics, the so-called MLS phenotype (strain SF4); (ii) high-level resistance to lincosamides and oleandomycin; partial resistance to spiramycin, carbomycin, tylosin, josamycin, and rosaramicin; and susceptibility to erythromycin (strain SF19); (iii) highlevel resistance only to a lincosamide antibiotic (lincomycin) and susceptibility to clindamycin, celesticetin, and macrolides (strain SF30); and (iv) high-level resistance to all the lincosamides and susceptibility to macrolides (strain SF31). A characteristic of the four types of high-level resistance to 421 VOL. 32, 1988 on January 11, 2018 by guest http://aac.asm.org/ Downloaded from lincomycin was susceptibility to erythromycin and vernamycin B (except in SF4).
Resistance to lincosamides resulting from the MLS resistance phenotype was the most abundant pattern (243 isolates; 20.0%). On the other hand, the resistance pattern showed by strain SF19 was found only in Arthrobacter species (18 isolates), being absent in the Staphylococcus species screened. Resistance phenotypes corresponding to strains SF27, SF28, SF30, and SF31 were not very frequent among the isolates, being detected in 17, 4, 1, and 6 isolates, respectively. Two standard susceptible strains (Staphylococcus aureus and Staphylococcus epidermidis) were similarly susceptible to lincomycin (and also to the other lincosamides, macrolides, and streptogramins) and, therefore, we chose S. aureus ATCC 25923 as a control susceptible strain for further experiments.
Susceptibility of the different strains to other groups of antibiotics was also tested by disk diffusion tests. While the standard susceptible strain (S. aureus ATCC 25923) was susceptible to most of the antibiotics, the different lincosamide-resistant strains were resistant to at least four antibiotics. In some cases (strains SF4, SF28, and SF31), resistance to seven antibiotics (two P-lactam antibiotics and at least three aminoglycosides) was found.
Effect of antibiotics on cell growth. Addition of erythromycin, lincomycin, or clindamycin (each at 50 ,ug/ml) to S.
aureus ATCC 25923 growing exponentially in L broth at 37°C completely stopped growth of the culture (Fig. 1) . However, the growth of strains SF19 and SF31 ( Fig. 1) damycin caused only a reduction in the growth rate. Similar growth inhibition was found with strain SF4 (data not shown). In contrast, the growth of strain SF30 (Fig. 1) was abolished by erythromycin and clindamycin and completely unaffected by the presence of lincomycin.
Sensitivity of in vivo protein synthesis to antibiotics. Having established the resistance patterns of the different strains, we decided to determine the effect of the antibiotics on protein synthesis by intact cells. Therefore, we measured the incorporation of [3H]leucine into TCA-insoluble material in the presence and absence of the antibiotics. For this and subsequent experiments, we discarded strain SF4 since the molecular basis of the MLS resistance phenotype has been described. Three of the five lincosamide-resistant strains (SF19, SF30, and SF31) were unaffected by lincomycin concentrations of up to 100 ,ug/ml (Fig. 2) ; the other two strains (SF27 and SF28) were partially affected by lincomycin but were less susceptible to the antibiotic than the control strain. Similar results (data not shown) were obtained with clindamycin.
Strain SF19 was selected to test the correspondence between MICs and the sensitivity of in vivo protein synthesis. This strain was challenged with different concentrations of lincomycin, clindamycin, erythromycin, oleandomycin, spiramycin, and carbomycin. The results (Fig. 3) 50 ,tg/ml, respectively), and sensitive to erythromycin (MIC, '1 ,ug/ml).
In conclusion, in vivo protein synthesis by strains SF19, SF30, and SF31 was totally resistant to lincomycin, while that of strain SF27 and SF28 was partially resistant.
Sensitivity of ribosomes to antibiotics. The possibility remained that in vivo resistance of protein synthesis displayed by the different strains might have been due to the inability of the antibiotics to penetrate the cell wall and the cytoplasmic membrane of the resistant strains. To check this, 70S ribosomes were isolated from the different resistant strains and their activity was measured in an in vitro translation system in the absence and presence of antibiotics. Comparison of the in vitro and in vivo resistance patterns of the different strains revealed a close correspondence; those antibiotics which did not inhibit growth failed to affect poly(U)-dependent polyphenylalanine synthesis in vitro. Ribosomes of strains SF19 and SF31 were insensitive to lincomycin (Fig. 4A) and clindamycin (Fig. 4B) but could be differentiated in their response to macrolides. Thus, those from strain SF31 were very sensitive to spiramycin and carbomycin, while ribosomes from strain SF19 were only partially affected by these drugs (Fig. 5) . Thus, resistance to antibiotics in these strains is ribosomal in nature. In contrast, ribosomes of strains SF27, SF28, and SF30 were sensitive to low concentrations of lincomycin (Fig. 4A) and clindamycin (Fig. 4B) . Therefore, resistance to lincosamides in strain SF27, SF28, and SF30 is not located in the ribosomes.
Assay of lincosamide-inactivating enzymes. Leclercq et al. (24) reported a strain of S. haemolyticus which inactivated lincomycin and clindamycin when whole cells were incubated with the antibiotics. We could not detect such inactivation of lincomycin or clindamycin in our lincosamideresistant strains. Moreover, we also failed to detect inactivation of the antibiotics when cell extracts of these strains were supplemented with ATP and acetyl coenzyme A as potential cofactors for drug modification. Ribosomes (25 pmol) were incubated for 5 min at 37°C with different concentrations of lincomycin or clindamycin. Then the assay of protein synthesis was initiated by adding the remaining components of the reaction mixture, as described in Materials and Methods. After 45 min at 37°C, the assay was stopped by removing 10-,ul samples and adding them to 1 ml of 10%o (wt/vol) TCA. The radioactivity incorporated into TCA-insoluble material was then determined after processing of the samples as described in references 11, 16, and 35) . Many of the genes mediating resistance to MLS antibiotics in clinical isolates are borne by plasmids, and the molecular basis for the resistance is understood (22, 23) . The second one, inactivation of the antibiotic, has been described only in staphylococci from different origins (14, 24) , and, at least in one case, the inactivating enzyme has been shown to be encoded by a plasmid (24) . In both cases, the biochemical basis of the inactivation is not known. On the other hand, in nonclinical isolates, high-level-lincomycin-resistant mutants have been isolated from Escherichia coli which had altered ribosomal proteins (either in the S7 protein of the 30S subunit or in L14 or L15 of the 50S subunit) (19) . However, in these cases, a relation between the altered proteins and lincomycin resistance could not be proved. In addition, lincosamide-modifying enzymes have been described in Streptomyces spp. which phosphorylate (1, 8, 9) or adenylylate (2) .
The strains we describe here (SF19, SF27, SF28, SF30, and SF31) present at least two lincosamide resistance mechanisms that were not previously described. Firstly, constitutive ribosomal resistance to all the lincosamides is shown by Arthrobacter species (strains SF19 and SF31). These strains possess different patterns of resistance to macrolides, SF19 being resistant to several macrolides (but not to erythromycin) and SF31 being resistant only to lincosamides. We do not know whether strain SF19 has a unique modification in the 50S subunit conferring resistance to both macrolides and lincosamides or two independent ribosomal modifications, each making the ribosomal particle insensitive to a specific group of antibiotics. However, whatever the basis is, it represents modification(s) in the lincosamide ribosome-binding site which confers resistance to lincosamides independently of the MLS resistance phenotype.
Another interesting point is the finding that both strains were susceptible to erythromycin. Lincomycin and erythromycin bind to the ribosome in partially or overlapping binding sites (but with different affinities), and cross-resistance to these antibiotics is therefore commonly observed. However, cross-resistance to lincomycin and erythromycin does not exist in strains SF19 and SF31, indicating the high selectivity of the modification in the lincosamide-binding site.
Secondly, there may be a permeability barrier to lincosamides in three strains of staphylococci (namely, SF27, SF28, and SF30). This hypothesis is supported by two lines of experimental evidence. (i) 70S ribosomes of these strains were sensitive in vitro to lincosamides. (ii) We could not find any specific lincosamide-inactivating enzyme either in cell extracts or in intact cells of these strains. Many, if not all, hydrophilic antibiotics with intracellular target sites are probably actively accumulated by the cells using nutrient transport systems (6) . This could be achieved by uptake systems for different solutes, as has been reported for fosfomycin (21, 37) . In addition, it has been proposed (13) that aminoglycoside antibiotics enter cells by various transport systems (uptake systems for sugars, amino sugars, polyamines, and amino acids) which have slightly different affinities for different aminoglycosides. The alteration of some solute-uptake systems able to transport lincosamides inside the cells could explain the growth of strains SF27, SF28, and SF30 in the presence of lincosamides. Interestingly, strain SF30 was highly resistant only to lincomycin and was susceptible to clindamycin and celesticetin, while strains SF27 and SF28 showed resistance to the three lincosamides, although only at a low level. Therefore, at least in strain SF30, the alteration must be very selective. A possible explanation is the existence of independent uptake systems for lincosamides with different affinities for these antibiotics. Such a situation could explain the difference in the patterns of resistance to lincosamides observed in SF30 compared with strains SF27 and SF28.
